Mitogenic hormones and tumor promoters greatly increase the incidence of colony-forming cells bearing amplified dihydrofolate reductase genes by Barsoum, James & Varshavsky, Alexander
Proc. Nati. Acad. Sci. USA
Vol. 80, pp. 5330-5334, September 1983
Cell' Biology
Mitogenic hormones 'and tumor promoters greatly increase the
incidence of colony-forming cellswbearing amplifieddihydrofolate reductase genes
(methotrexate resistance/phorbol esters/mezerein/mitogenic hormones/disproportionate DNA replication)
JAMES BARSOUM AND.ALEXANDER VARSHAVSKY
Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139
Communicated by Gerald N. Wogan, May 23, 1983
ABSTRACT Previous work has shown that the presence of a
phorbol ester tumor promoter, phorbol 12-myristate 13-acetate
(PMA), during a single-step selection for methotrexate (MTX)-re-
sistant mouse 3T6 cells results in an up to 100-fold increase in the
incidence of MTX-resistant, colony-forming cells. MTX resistance
of most of these cells is due to amplification of the gene for dihy-
drofolate reductase (DHFR), the target enzyme for MTX. We show
here that other active, noncytotoxic.phorbol ester tumor pro-
moters, such as phorbol 12, 13-didecanoate and 20-phorbol 12,13-
butyrate, at their optimal concentrations (JO. 1 jtM) are approx-
imately equal to PMA in increasing the incidence of MTX-resis-
tant 3T6 colonies. Mezerein, a potent second-stage tumor pro-
moter, but a weak complete promoter, increases the incidence of
MTX resistance up to 350-fold, the strongest effect for any of the
agents so far tested. PMA analogs that are inactive as tumor pro-
moters, such as phorbol or phorbol 12,13,20-triacetate, have no
effect on the incidence of MTX-resistant 3T6 colonies. Anthralin,
a nonphorbol tumor promoter, is -40% as active as PMA in the
MTX selection assay. Remarkably, the hormones insulin, arginine
vasopressin, and epidermal growth factor, all of which are mi-
togenic for 3T6 cells, also exert a strong PMA-like effect on the
incidence of MTX-resistant 3T6 colonies under conditions of MTX
selection. The effect of insulin at its optimal concentration (-1
,.g/ml) is =70% that of PMA. Although the effect of PMA on the
incidence of MTX-resistant 3T6 colonies does not significantly de-
pend on the initial density of seeded cells or volume of the me-
dium added, the analogous effect of insulin is strongly influenced
by these parameters. Mevalonic acid, arachidonic acid, thymi-
dine, caffeine, and nicotine, all of which are known to influence
patterns of DNA synthesis in mammalian cells, were tested at their
highest noncytotoxic concentrations and failed to produce any sig-
nificant effect on the incidence of MTX-resistant 3T6 colonies.
We discuss possible -mechanisms of hormone- and tumor pro-
moter-facilitated gene amplification in mammalian cells, rela-
tionship of mitogenic hormones to tumor promoters, and also im-
plications of our findings for the problem of drug resistance in
cancer chemotherapy.
'We have recently reported that phorbol 12-myristate 13-acetate
(PMA), a noncytotoxic, nonmutagenic phorbol ester.tumor pro-
moter, greatly increases the incidence of mouse cells bearing
amplified dihydrofolate reductase (DHFR) genes under con-
ditions of cytotoxic selection for resistance to a DHFR enzyme
inhibitor, methotrexate (MTX) (1). Subsequent work by Tlsty
et al. (2) has confirmed this result and, in addition, showed that
cytotoxic treatments of mammalian cells (with hydroxyurea or
UV light) before selection for MIX resistance also lead to an
increased incidence of colony-forming cells'bearing amplified
DHFR genes. These findings (1, 2) provided an indirect sup-
port for an earlier hypothesis that one pathway of carcinogen-
esis and tumor progression may operate through a generalized
increase in thefrequency of disproportionate DNA replication
within a single cell cycle, resulting in accelerated gene ampli-
.fication (3). Targets for such "facilitated" gene amplification may
include genes responsible for the initial stages of carcinogenesis
or other genetic loci--.for example, those influencing metastatic
potential or immunosuppressive properties of-evolving,tumor
cells (3-12). Facilitated gene amplification could greatly speed
up evolution of cellular systems under selection pressure, a de-
veloping tumor being one example of such a system. Indeed,
double-minute chromosomes (DMs) and homogeneously stain-
ing chromosomal regions (HSRs), the two cytological indicators
of gene amplification (5, 13-15), have been consistently de-
*tected in cells from a wide variety of naturally occurring tumors
but were not reported to occur in cells from normal tissues (9).
A different aspect of gene amplification that is also clinically
-important is the emergence of drug-resistant tumor cells dur-
ing cancer chemotherapy. In many cases such cells are drug-
resistant due to amplification of specific genes whose products
are involved with drug's action, transport, or metabolism (5, 9,
14-16).
We report below that tumor-promoting phorbol esters other
than PMA, nonphorbol tumor promoters, and most signifi-
cantly, mitogenic hormones, such as insulin, vasopressin, and
epidermal growth factor (EGF), also greatly increase the in-
cidence of MTX resistance in 3T6 cells under conditions of MTX
selection.
MATERIALS AND METHODS
Single-Step-MTX Selection Assay. The procedure was de-
scribed-in detail previously (1). MTX [(+)amethopterin], bo-
vine insulin, and arginine vasopressinwere obtained from Sigma.
Phorbol derivatives were obtained from Consolidated Midland
(Brewster, NJ). Mezerein was obtained from CCR (Eden Prai-
rie, MN). EGF was obtained from Bethesda Research Labo-
ratories.
Cloning of MTX-Resistant 3T6 Cells and DNA Isolation.
The protocol used was essentially the one described previously
(1, 17), except that a dot blot manifold (Schleicher & Schuell)
was used, and quantitation of dot hybridization patterns was
carried out by cutting out and counting individual dots of 32P-
Abbreviations: DHFR, dihydrofolate reductase; PMA, phorbol 12-my-
ristate 13-acetate; PDD, phorbol 12,13-didecanoate; PDBu, 20-phorbol
12,13-butyrate; PTA, phorbol-12,13,20-triacetate; MTX, methotrexate;
EGF, epidermal growth factor; MVA, mevalonic acid; Me2SO,. dimethyl
sulfoxide; DMs, double-minute chromosomes; HSR, homogeneously
staining region.
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labeled DNA (this procedure yields more accurate results than
visual comparisons of dot intensities; data not shown). The cloned
mouse DHFR cDNA probe (pDHFRi1; ref. 18) was a gift from
R. Schimke. The cloned mouse Iraj-globin cDNA probe (pCR1-
M9; ref. 19) was donated by V. Volloch.
RESULTS
Incidence of MIX-Resistant 3T6 Colonies Is Greatly In-
creased in the Presence of Either Phorbol or Nonphorbol Tu-
mor Promoters. Fig. 1A shows that the presence of PMA dur-
ing MTX selection results in up to a 100-fold increase in the
incidence of MTX-resistant mouse 3T6 cell colonies, as de-
scribed in detail'previously (1). The enhancing effect of PMA
varied from one independent experiment to another from -50-
fold to 110-fold, whereas duplicate plates within one and the
same experiment.showed <20% variation (ref. 1 and data not
shown). Whenever a comparison was made between the effect
of PMA and of another compound on the incidence of MTX
resistance (see below), measurements of the PMA effect were
carried out in a parallel experiment with the same population
of 3T6 cells.
Using the same single-step MTX selection assay (1), we have
subsequently tested other phorbol esters and found that phor-
bol 12,13-didecanoate (PDD) and 20-phorbol 12,13-butyrate
(PDBu), both of which.are comparable to PMA in their tumor
promoting activity on mouse skin (20-24), are also approxi-
mately equal to PMA in increasing the incidence of MTX-re-
sistant 3T6 colonies (Fig. 2). Optimal concentrations of PDD
and PDBu in the MTX selection assay were determined as de-
scribed for PMA (1) (data not shown) and were found to be in-
distinguishable from the optimal PMA concentration (0O. 1 /IM;
ref. 1). On the other hand, the addition of either a weak phor-
bol ester tumor promoter phorbol 12,13,20-triacetate (PTA) or
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FIG. 1. Effects of PMA and mezerein on incidence of 3T6 cells bearing amplified DHFR genes; determination of DHFR gene dosage. (A) Con-
fluent 3T6 monolayers in medium A were reseeded in 10-cm plates (1.5 x 106 cells per plate) containing MTX in the same medium (1). *, 3T6 cells
grown, reseeded, and selected in the absence ofPMA; x, same, butPMA was added at 162 nM (0.1 pug/ml) at the start ofMTX selection. (B) Relative
DHFR gene dosage in MTX-resistant 3T6 cells as a function ofselectingMTX concentration. Experimental points in this graph were derived directly
from the dot hybridization data (shown in D). (C) Stained colonies ofMTX-resistant 3T6 cells (1.5 x 106 cells initially seeded per plate in the presence
of 150 nM MTX) selected in the absence of PMA and mezerein (plate a), in the presence of 162 nM PMA (plate b), or in the presence of 162 nM
mezerein (plate c). Plate d is the same as plate c, but 1.85 x 106 3T6 cells were initially seeded. (D) Determination of relative DHFR gene dosages
in MTX-resistant 3T6 cells by a DNA-DNA dot hybridization assay. Equal amounts of the total nuclearDNA (1Ug) purifiedfrom different sublines
were denatured, applied onto a nitrocellulose filter, and hybridized with the cloned 32P-labeled DHFRcDNA (pDHFR11; see Materials and Methods
and ref 18). An identical parallel set ofDNA dots was hybridized with cloned 32P-labeled ("'-globin cDNA probe (pCRI-M9; data not shown; see
Materials and Methods and refs. 1 and 19). All dots represent independently selected MTX-resistant 3T6 sublines. DNA from control, MTX-sensitive
3T6 cells (dots 2a, 4a, 51, and 6a). DNA from 3T6 cells selected for resistance to 100 nM MTX in the presence of either 162 nM mezerein (dot id)
or 162 nM PMA (dots 2g, 6c, and 7e) or insulin at 1 jug/ml (dots if and 5j) or no additions (dot 2e). DNA from 3T6 cells selected for resistance to
150 nM MTX in the presence of either 162 nM mezerein (dots lb and 5h) or 162 nM PMA (dots 3b, 3h, 31, and 6g) or insulin at 1 '"g/ml (dots lj,5d, and 6i) or no additions (dots 2c, 2k, and 3d). DNA from 3T6 cells selected for resistance to 200 nMMTX in the presence of either 162 nM mezerein(dot 3f) or 162 nM PMA (dots 4i and 5f) or insulin at pg/ml (dot 4e) or no additions (dots lh and 4g). DNA from 3T6 cells selected for resistance
to 300 nM MTX in the presence of either 162 nM PMA (dot 6k) or insulin at, 1 pg/ml (dot 3j) or no additions (dot 2i).
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FIG. 2. Influence of various noncytotoxic agents on incidence ofMTX
resistance in 3T6 cells. Confluent 3T6 monolayers were reseeded at 1.5
x 106 cells per 10-cm plate in the presence of 150 nM MTX and one of
the following agents: a, PMA; b, PDD; c, PDBu; d, PTA; e, phorbol; or
f, mezerein (a-f at 162 nM); g, anthralin (10 nM); h, 0.01% dimethyl
sulfoxide (Me2SO); i, 0.1% Me2SO; j, insulin (1 pig/ml); k, arginine va-
sopressin (10 ng/ml); l, EGF (10 ng/ml); m,. mevalonic acid (MVA)- (1
mM); n, arachidonic acid (100 nM); o, thymidine (20 ,uM); p, caffeine (50
AWM); q, nicotine (60 ,tM); r, no addition (control). For the tumor pro-
moters and hormones the concentration listed is that which resulted in
the greatest incidence of MTX-resistant 3T6 colonies. Nicotine and caf-
feine were present at their highest noncytotoxic levels as determined
by a plating efficiency assay (1).
a nonpromoting phorbol (20, 21, 23, 24) to a MTX assay did not
significantly increase the incidence of MTX-resistant 3T6 col-
onies (Fig. 2). Anthralin, a relatively weak nonphorbol tumor
promoter (23, 25), is =40% as active as PMA in the MTX se-
lection assay at an optimal anthralin concentration (-=10 nM)
(Fig. 2). None of the compounds listed in Fig. 2 is itself cy-
totoxic for 3T6 cells at concentrations used, as was verified by
plating efficiency measurements carried out as described (1).
Mezerein, a Second-Stage Tumor Promoter, Is the Most
Potent of Known Noncytotoxic "Enhancers" of the Incidence
of MTX Resistance in 3T6 Cells. Mezerein is a macrocyclic plant
diterpene that is structurally related to phorbol esters and has
many of the same effects as PMA in cell culture but is consid-
erably weaker than PMA when tested alone as a tumor pro-
moter on mouse skin (20, 26). However, mezerein was shown
to be quite potent when used during the second stage of tumor
promotion as defined by using the mouse skin model (20-22,
26). We found mezerein to increase the incidence of MTX-re-
sistant 3T6 colonies "'350-fold as compared with an =110-fold
increase elicited by PMA under the same conditions in a par-
allel MTX selection experiment (Figs. 2 and 3).
Hormones Insulin, Arginine Vasopressin, and EGF All In-
crease the Incidence of MTX-Resistant 3T6 Colonies Under
Conditions of MTX Selection. As shown in Figs. 2-4, addition
of optimal concentrations of either insulin, arginine vasopres-
sin, or EGF to the MTX selection assay results in an "'70-fold,
"'60-fold, or "'50-fold increase, respectively, of the incidence
of MTX-resistant 3T6 colonies, as compared with an '110-fold
increase elicited by PMA under the same conditions in a par-
allel series of single-step MTX selections. A significant ("'3-fold)
increase in the incidence of MTX-resistant 3T6 colonies is caused
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FIG. 3. Incidence of MTX-resistant 3T6 colonies as a function of
initial cell density in the presence of either insulin, PMA, or mezerein.
Varying amounts of 3T6 cells were seeded in 10-cm plates in medium
A containing 150 nM MTX and either no additions (e), insulin (1 ,ug/
ml; 0), PMA (162 nM; x), or mezerein (162 nM; Ax).
by insulin even at 10 ng/ml, which is 1/100th of the optimal
insulin concentration (Fig. 2 and data not shown). All of the
above hormones as well as PMA and other tumor-promoting
phorbol esters are mitogenic and noncytotoxic for 3T6 cells at
the concentrations used (refs. 1, 27, and 28 and data not shown).
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FIG. 4. Incidence of MTX-resistant 3T6 colonies as a function ofthe
volume of medium per plate during MTX selection: comparison of the
effects of insulin and PMA. Confluent 3T6 cells in medium A were re-
seeded at 0.9 x 106 cells per 10-cm plate in the same medium containing
150 nM MTX and either no additions (s), insulin (1 ,ug/ml; 0), or PMA
(162 nM; x) in volumes of the medium varying from 15 to 45 ml per plate.
x
x
Proc. Natl. Acad. Sci. USA 80 (1983)
_
Proc. Natl. Acad. Sci. USA 80 (1983) 5333
Most of MTX-Resistant 3T6 Clones Have Increased Dos-
ages of DHFR Genes. Mouse cells were shown to acquire re-
sistance to MTX either through an amplification of the DHFR
gene, which leads to an overproduction of the target DHFR
enzyme (5, 9-12, 18), through mutations rendering the DHFR
enzyme less sensitive to inhibition by MTX, or through mu-
tations decreasing MTX uptake by cells (5). Of these causes of
MTX resistance, the DHFR gene amplification appears to be
the most frequent one under a variety of conditions (5, 9-12).
This is in agreement with the results shown in Figs. 1 B and D
for 3T6 sublines that were single-step selected for resistance to
different MTX concentrations either in the presence or absence
of PMA, mezerein, or insulin. Of 38 independently derived
3T6 sublines selected for resistance to different concentrations
of MTX in the presence of added PMA, insulin, or mezerein,
only 4 sublines (3 resistant to 100 nM MTX and 1 resistant to
200 nM MTX) did not have an increased DHFR gene dosage
(Fig. ID, dot 6c and data not shown). Significantly, it is the
selecting MTX concentration but not the presence of tumor
promoters or hormones that determines the DHFR gene dos-
age in MTX-resistant 3T6 clones as has been found previously
for the PMA-MTX system (1) and is shown in Fig. ID for the
mezerein-MTX and insulin-MTX systems.
Insulin Effect on Incidence of MTX-Resistance in 3T6 Cells
Strongly Depends on Initial Cell Density and Volume of Added
Medium During MTX Selection. When the amount of 3T6 cells
seeded per a 10-cm plate at the start of selection for resistance
to 150 nM MTX in the presence of insulin is increased less than
50% from 0.9 x 106 to 1.5 X 106 cells per plate, the incidence
of MTX resistant 3T6 colonies is increased ==25-fold, from -1
x 10-6 to -2.5 x 10-5 (Fig. 3). Analogous effects of arginine
vasopressin and EGF display a strikingly similar dependence
on the initial cell density (data not shown). In contrast, in a par-
allel single-step MTX selection in the presence of PMA, the
increase in the number of initially seeded 3T6 cells from 0.9 X
106 to 1.5 X 106 cells per plate resulted in a relatively small
increase in the incidence of MTX-resistant 3T6 colonies, from
==4 x 10-5 to
-6 x 10-5 (Fig. 3). Selection experiments car-
ried out in the presence of mezerein, PDD, PDBu, or anthralin
also did not show a significant dependence of the incidence of
MTX resistance on the initial cell density, in striking contrast
to the results with the insulin-MTX system (Fig. 3 and data not
shown).
The fact that insulin added to the 3T6 growth medium is much
less metabolically stable than PMA (29) apparently does not
contribute to the results shown in Fig. 3 because experiments
in which insulin was added to 3T6 cultures at either 4- or 12-
hr intervals from the start of MTX selection produced similar
results (data not shown). It should be also noted that a decrease
in the initial cell density significantly below 0.9 X 106 cells per
a 10-cm plate does lead to a significant decrease in the inci-
dence of MTX-resistant 3T6 cells selected in the presence of
either PMA (1) or mezerein (data not shown).
To explain the much stronger effect of the initial cell density
on the incidence of MTX-resistant colonies selected in the
presence of insulin versus PMA, it is sufficient to assume that
although both compounds are mitogenic for partially MTX-re-
sistant 3T6 cells that emerge during MTX selection, PMA is
either a more potent mitogen or requires lower concentrations
of MTX block-bypassing compounds (released from dying, MTX-
sensitive cells) in the medium to induce growth of "nascent"
MTX-resistant cells. The finding that the insulin-mediated in-
crease in the incidence of MTX resistance has a far greater de-
pendence on the volume of medium added per plate as com-
pared with the PMA-mediated effect (Fig. 4) is also consistent
with the above explanation.
Effects of PMA and Insulin Present Together During MTX
Selections Are Approximately Additive. At all of the cell densi-
ties tested, from 1 x 106 to 1.75 X 106 3T6 cells per a 10-cm
plate, the effect of simultaneous presence of optimal concen-
trations of insulin and PMA is approximately equal to the sum
of the effects of insulin and PMA alone (Fig. 5). In contrast,
the effect of simultaneous presence of optimal concentrations
of PMA and another phorbol ester promoter, PDD (Fig. 2), on
the incidence of MTX resistance is indistinguishable from the
effects of each of these compounds present alone in the MTX
selection assay (data not shown). One interpretation of these
results is that there may be little overlap between the sets of
cell targets for growth-promoting activities of PMA and insulin
in the nascent population of MTX-resistant 3T6 cells.
MVA, Arachidonic Acid, Thymidine, Caffeine, and Nico-
tine Do Not Significantly Change the Incidence of MTX Re-
sistance in 3T6 Cells. All of the above compounds are known
to influence patterns of DNA synthesis in mammalian cells.
Arachidonic acid (a prostaglandin precursor) and MVA, the rate-
limiting intermediate in cholesterol biosynthesis, have both been
shown to increase in concentration after PMA treatment (30).
Addition of MVA or arachidonic acid to cell cultures stimulates
DNA synthesis (31). Plant alkaloids caffeine and nicotine also
stimulate DNA synthesis by subconfluent cell cultures (32, 33).
Presence of a nucleotide precursor thymidine in the growth
medium has been shown to increase the plating efficiency of
3T6 cells (1). As shown in Fig. 2, none of the above compounds,
when tested at its highest noncytotoxic concentrations in the
single-step MTX selection assay, significantly increases the in-
cidence of MTX-resistant 3T6 colonies.
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FIG. 5. Effect of simultaneous presence ofPMA and insulin during
MTX selection of 3T6 cells is approximately additive as compared with
effects of PMA and insulin alone. Varying amounts of confluent 3T6
cells in medium A were reseeded in 10-cm plates in the same medium
containing 150 nM MTX and either no additions (e), insulin (1,g/ml;
o), PMA (162 nM; x), or both PMA and insulin at the above concen-
trations (o). The dashed curve shows the calculated "precise additivity"
pattern produced by summing up the effects of PMA and insulin when
present separately in the single-step MTX selection assay.
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DISCUSSION
Possible Mechanisms of Hormone- and Tumor Promoter-
Increased Incidence of Cells Bearing Amplified Genes. There
are two classes of interpretations formally consistent with our
results. In the first one, the presence of either tumor pro-
moters or hormones in the single-step MTX selection assay in-
creases (either directly or indirectly) the probability of gene
amplification through disproportionate DNA replication (1, 3,
5) in many different chromosomal domains, including the one
containing the DHFR gene. In the second class of interpre-
tations, tumor promoters and hormones do not increase the
probability of gene amplification per se, but rather the prob-
ability of colonyformation by either preexisting or newly formed
cells bearing amplified DHFR genes. A qualitative correlation
between the ability of a substance to act as a mitogen for 3T6
cells and its ability to increase the incidence of MTX-resistant
3T6 colonies (see Results) is consistent with the second class of
interpretations but also with one interpretation from the first
class-namely, that while cytotoxic conditions of selection may
"prime" cells for an increased probability of disproportionate
DNA replication, the action of a mitogenic substance, such as
PMA or insulin, is also required for a cell to enter a "replicative
state" (analogous but not necessarily identical to a normal S-phase
state) where the disproportionate DNA replication would ac-
tually occur (see also refs. 34 and 35). Taken together, our data
favor both of these two related pathways in which mitogenic
hormones and tumor promoters act by increasing both the
probability of disproportionate DNA replication (via increased
numbers of cells entering a replicative state in the presence of
a cytotoxic drug) and the probability of survival and colony for-
mation by nascent mutant cells bearing amplified genes.
Another means by which the incidence of MTX-resistant cell
colonies can be increased is by briefly treating the cells with a
cytotoxic agent other than MTX (such as hydroxyurea or UV
light) shortly before subjecting them to MTX selection (ref. 2;
see also refs. 23 and 35). The effect of these transient cytotoxic
treatments on the yield of cells bearing amplified genes is likely
to be due to a direct influence of the above cytotoxic agents on
the probability of disproportionate DNA replication (2, 3, 34,
35), in contrast to the proposed mechanism by which the anal-
ogous effect is produced indirectly through the use of noncy-
totoxic, mitogenic hormones and tumor promoters.
One interpretation of the striking similarity of hormones and
tumor promoters in the gene amplification assay (see Results)
is that noncytotoxic tumor promoters such as phorbol esters act
in their tumor-promoting mode as nothing more than powerful,
cell type-specific mitogens. Both the fact that a number of
mammalian hormones have been shown to possess tumor-pro-
moting properties (36-38) and the recent identification of a
phorbol ester receptor as a specific protein kinase (39, 40) are
consistent with the "mitogenic" interpretation of the phenom-
enon of tumor promotion (see, however, refs. 41 and 42).
Significance of Hormone-Facilitated Gene Amplification
for the Problem of Drug Resistance in Cancer Chemotherapy.
Extensive evidence on drug resistance in both animal and hu-
man tumors strongly suggests that resistance of tumor cells to
either a single cytotoxic drug, such as MTX (5, 9-12), or to a
number of different drugs (16) simultaneously is often due to
amplification of specific genes or sets of genes during cytotoxic
selection for such drug-resistant cells in cancer chemotherapy.
Regardless of which of the suggested mechanisms of the hor-
mone-facilitated gene amplification (see above) will prove to be
the correct one, it is clear that the incidence of colony-forming
drug-resistant cells can vary dramatically in vitro, depending
on the conditions of selection (see Results and refs. 1 and 2).
One implication of this discovery is that by manipulating the
conditions of cytotoxic chemotherapy of tumor cells it may be
possible to reduce the incidence of drug-resistant cells.
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